Gyre Therapeutics (GYRE) announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial” in the Journal of Clinical and Translational Hepatology. This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B. The published protocol outlines patient inclusion criteria, randomization and blinding processes, key assessments, and the statistical analysis plan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings
- Impact of New U.S. Regulations on Gyre Therapeutics: Potential Delisting Risks and Investor Concerns
- Catalyst Biosciences Inc trading resumes
- Catalyst Biosciences Inc trading halted, volatility trading pause
- Gyre Therapeutics reports Q4 EPS 0c vs. ($1.39) last year